Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytoreduction Surgical Procedures | 4 | 2020 | 12 | 2.030 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 30 | 1.800 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2021 | 14 | 1.460 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2019 | 8 | 1.380 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 91 | 1.370 |
Why?
|
| Hyperthermia, Induced | 3 | 2019 | 20 | 1.360 |
Why?
|
| Surgical Wound Infection | 3 | 2016 | 124 | 1.260 |
Why?
|
| Anastomosis, Surgical | 3 | 2019 | 118 | 1.210 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 309 | 1.110 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 286 | 1.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 463 | 1.060 |
Why?
|
| Rectal Neoplasms | 6 | 2024 | 138 | 1.000 |
Why?
|
| Postoperative Complications | 9 | 2024 | 1313 | 0.940 |
Why?
|
| Neoadjuvant Therapy | 7 | 2024 | 99 | 0.910 |
Why?
|
| Vascular Surgical Procedures | 4 | 2016 | 240 | 0.900 |
Why?
|
| Propensity Score | 3 | 2019 | 189 | 0.810 |
Why?
|
| Survival Rate | 8 | 2021 | 843 | 0.740 |
Why?
|
| Neoplasms | 3 | 2025 | 1363 | 0.740 |
Why?
|
| Abdomen | 1 | 2021 | 94 | 0.680 |
Why?
|
| Pancreatectomy | 1 | 2021 | 99 | 0.650 |
Why?
|
| Sarcoma | 1 | 2020 | 36 | 0.640 |
Why?
|
| Blood Transfusion | 1 | 2021 | 164 | 0.630 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 9 | 0.630 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 31 | 0.620 |
Why?
|
| Length of Stay | 3 | 2020 | 824 | 0.580 |
Why?
|
| Hepatectomy | 1 | 2019 | 63 | 0.570 |
Why?
|
| Intensive Care Units | 1 | 2021 | 420 | 0.550 |
Why?
|
| Population Surveillance | 1 | 2019 | 210 | 0.540 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 2473 | 0.510 |
Why?
|
| Prognosis | 6 | 2021 | 1772 | 0.490 |
Why?
|
| Telemedicine | 3 | 2016 | 363 | 0.480 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 364 | 0.480 |
Why?
|
| Retrospective Studies | 15 | 2024 | 6818 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 630 | 0.470 |
Why?
|
| Humans | 33 | 2025 | 64768 | 0.460 |
Why?
|
| Checklist | 1 | 2016 | 69 | 0.460 |
Why?
|
| Palliative Care | 1 | 2018 | 246 | 0.450 |
Why?
|
| Smartphone | 1 | 2016 | 73 | 0.450 |
Why?
|
| Cell Phone | 1 | 2015 | 41 | 0.440 |
Why?
|
| Aged | 15 | 2024 | 14882 | 0.440 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 165 | 0.430 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 371 | 0.420 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 642 | 0.410 |
Why?
|
| Cholecystostomy | 2 | 2011 | 22 | 0.400 |
Why?
|
| Cholecystitis, Acute | 2 | 2011 | 30 | 0.400 |
Why?
|
| Patient Readmission | 2 | 2014 | 446 | 0.390 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 141 | 0.380 |
Why?
|
| Female | 21 | 2024 | 33804 | 0.360 |
Why?
|
| Male | 21 | 2024 | 30840 | 0.360 |
Why?
|
| Caregivers | 1 | 2015 | 292 | 0.350 |
Why?
|
| Middle Aged | 16 | 2024 | 18156 | 0.350 |
Why?
|
| Quality of Life | 2 | 2018 | 1254 | 0.340 |
Why?
|
| Intubation | 1 | 2010 | 10 | 0.320 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 626 | 0.320 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2010 | 49 | 0.310 |
Why?
|
| Treatment Outcome | 7 | 2024 | 5765 | 0.300 |
Why?
|
| Reoperation | 2 | 2021 | 300 | 0.270 |
Why?
|
| United States | 7 | 2024 | 8052 | 0.270 |
Why?
|
| Survival Analysis | 2 | 2020 | 576 | 0.260 |
Why?
|
| Chemoradiotherapy | 2 | 2024 | 75 | 0.260 |
Why?
|
| Laparoscopy | 2 | 2024 | 489 | 0.240 |
Why?
|
| Webcasts as Topic | 1 | 2025 | 1 | 0.240 |
Why?
|
| Blogging | 1 | 2025 | 11 | 0.230 |
Why?
|
| Retroperitoneal Space | 2 | 2021 | 23 | 0.220 |
Why?
|
| Postoperative Care | 2 | 2016 | 125 | 0.220 |
Why?
|
| Margins of Excision | 1 | 2024 | 31 | 0.210 |
Why?
|
| Consolidation Chemotherapy | 1 | 2023 | 3 | 0.200 |
Why?
|
| Liposarcoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2016 | 518 | 0.180 |
Why?
|
| Pelvis | 1 | 2021 | 62 | 0.170 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 169 | 0.170 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2020 | 13 | 0.170 |
Why?
|
| Hepatic Artery | 1 | 2020 | 22 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2021 | 231 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 47 | 0.160 |
Why?
|
| Patient Admission | 1 | 2021 | 197 | 0.150 |
Why?
|
| Risk Factors | 3 | 2020 | 5392 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 372 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2021 | 497 | 0.140 |
Why?
|
| Critical Care | 1 | 2021 | 400 | 0.130 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 694 | 0.130 |
Why?
|
| Colon, Transverse | 1 | 2017 | 4 | 0.130 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Diverticulitis | 1 | 2017 | 33 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2015 | 2604 | 0.120 |
Why?
|
| Somatostatin | 1 | 2016 | 21 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 233 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 797 | 0.120 |
Why?
|
| Amygdala | 1 | 2016 | 85 | 0.120 |
Why?
|
| Colectomy | 1 | 2017 | 122 | 0.120 |
Why?
|
| Aging | 1 | 2021 | 760 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 216 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 1655 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 67 | 0.110 |
Why?
|
| Incidence | 1 | 2019 | 1410 | 0.110 |
Why?
|
| Aneurysm | 1 | 2015 | 58 | 0.110 |
Why?
|
| Cross Infection | 1 | 2016 | 164 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 230 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 162 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 141 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 601 | 0.100 |
Why?
|
| Adult | 5 | 2024 | 17251 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1380 | 0.100 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 234 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2016 | 275 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2020 | 3297 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2014 | 150 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 361 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 540 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2014 | 317 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 250 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1686 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 70 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 90 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 5590 | 0.080 |
Why?
|
| Neurons | 1 | 2016 | 932 | 0.080 |
Why?
|
| Stents | 1 | 2011 | 494 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 483 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 2090 | 0.060 |
Why?
|
| Rectum | 1 | 2024 | 96 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2021 | 62 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 6 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2020 | 39 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 242 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 581 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 2016 | 13 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 495 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 927 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2014 | 45 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 2014 | 33 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1097 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 880 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2014 | 85 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 1568 | 0.020 |
Why?
|
| Cholecystography | 1 | 2011 | 14 | 0.020 |
Why?
|
| General Surgery | 1 | 2014 | 211 | 0.020 |
Why?
|
| Critical Illness | 1 | 2011 | 328 | 0.020 |
Why?
|
| Massachusetts | 1 | 2014 | 2130 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 4772 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 6247 | 0.010 |
Why?
|